Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Written By: Nitin Goswami, Senior Medical Content Writer | Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Quick answer: Bile duct cancer (cholangiocarcinoma) starts in the tubes that carry bile from your liver to your intestine. It often shows up late, with yellow skin and eyes, itching, dark urine and pale stools. For advanced disease, the usual first treatment is chemotherapy (gemcitabine with cisplatin), and a trial showed that adding durvalumab helped people live longer. Testing the tumor can also find targets such as FGFR2, and for FGFR2 fusions there is a tablet called Lytgobi (futibatinib) for people who've already had treatment. In India it can be accessed through a Named Patient Program with a valid prescription.
Last reviewed: September 24, 2026. Every figure in this guide is sourced in the References section at the end.
Most people don't go looking for information on bile duct cancer until something has already gone wrong. Maybe the whites of your eyes turned yellow. Maybe you've been itching for weeks with no rash to explain it. Or maybe a scan has just used a word you've never heard: cholangiocarcinoma.
It's a lot to take in, and the internet doesn't help much. Most pages either stop at "it's rare and serious" or jump straight into medical jargon. This guide is meant to sit in the middle. We'll cover what bile duct cancer actually is, the signs to watch for, what raises the risk, how it's tested for, and what treatment looks like today, including the newer targeted options that most people only hear about late.
| Medical name | Cholangiocarcinoma (bile duct cancer) |
|---|---|
| Where it starts | Inside the liver (intrahepatic), where the liver ducts join (perihilar), or in the duct near the pancreas and intestine (distal) |
| Common signs | Yellow skin and eyes, itching, dark urine, pale greasy stools, pain under the right ribs, weight loss, fever |
| How common | About 8,000 people a year in the United States; average age is in the 70s (ACS) |
| Biomarkers worth asking about | FGFR2 fusions or rearrangements, IDH1 mutations, BRAF mutations, NTRK fusions |
| Usual first treatment (advanced) | Gemcitabine plus cisplatin, with durvalumab added in the TOPAZ-1 trial |
| Targeted option for FGFR2 | Lytgobi (futibatinib), approved by the U.S. FDA on September 30, 2022, for previously treated intrahepatic disease. See the Lytgobi page |
Your liver makes bile, a fluid that helps you digest fat. Bile travels out of the liver through a network of thin tubes, the bile ducts, and finally empties into the small intestine. Bile duct cancer, also called cholangiocarcinoma, is a cancer that starts in any part of that tube system.
Doctors sort bile duct cancer by where in the tube system it begins, because the location changes both the symptoms and the treatment options.
Intrahepatic tumors behave a little differently from the other two, and they're the group in which the FGFR2 change discussed later is most often studied. If you're reading your own report, look for the words "intrahepatic," "perihilar" or "distal." It's one of the first things worth confirming with your doctor.
Numbers can't predict what will happen to you, but they show how this cancer usually behaves and why early testing matters. Every figure below names its source.
These are 5-year relative survival rates from the SEER database for people diagnosed between 2015 and 2021, as reported by the ACS. They describe groups of people, not any one person, and treatment keeps changing.
One more number helps explain why doctors push for tumor testing. A plain-language summary of the FOENIX-CCA2 study notes that after a first round of chemotherapy, people with advanced bile duct cancer live a median of about 1 year, and about 6 months after a second. That gap is exactly what newer targeted treatments are trying to close.
Here's the hard part: bile duct cancer is often quiet in the beginning. The ACS says the symptoms usually appear once the cancer is more advanced. When a duct gets blocked, bile backs up, and that causes most of the signs you'll notice.
The ACS is clear that these signs are far more likely to come from something else, such as gallstones or hepatitis. That's the reassuring part. The practical part is that yellow eyes or skin, or persistent itching with dark urine, should always be looked at by a doctor, whatever the cause turns out to be.
For many people there's no clear cause, which is worth saying out loud, because patients often blame themselves. What researchers do know is that long-term irritation or scarring of the bile ducts raises the risk. The ACS lists these risk factors.
Having a risk factor doesn't mean you'll get the cancer, and many people diagnosed have none of them.
Diagnosis usually combines blood tests, imaging such as ultrasound, CT or MRI, and often a biopsy or a procedure to look inside the ducts. Your doctor will decide the exact mix. What's less commonly explained is the step that comes after: testing the tumor's genes.
A 2024 review in Targeted Oncology notes that up to half of cholangiocarcinomas carry genetic changes that can be treated with targeted medicines. A 2020 review in the Journal of Hepatology names the ones doctors look for in intrahepatic disease: FGFR2 and NTRK fusions, and IDH1 and BRAF mutations.
Treatment depends on where the cancer is, whether it can be removed, and what the tumor testing shows. Here's how the main pieces fit together.
When the cancer hasn't spread and the tumor can be removed, surgery is the approach that offers the best chance of long-term control. After surgery, capecitabine chemotherapy is the standard add-on described in the Journal of Hepatology review. Your surgical team will tell you whether your tumor is removable.
Then the focus moves to systemic treatment, meaning medicines that travel through the whole body.
For years the standard first treatment has been gemcitabine plus cisplatin. In the TOPAZ-1 trial, 685 people with previously untreated advanced biliary tract cancer received that chemotherapy with either durvalumab or a placebo.
That's a real gain, though a modest one, and it doesn't replace testing. Some people will also benefit from a targeted treatment later.
This is where testing pays off. If a tumor carries a specific alteration, a tablet designed for that alteration may be an option, usually after chemotherapy.
Lytgobi is a once-daily tablet that blocks FGFR1 to 4 irreversibly. The U.S. FDA granted it accelerated approval on September 30, 2022, for adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement. Here's what the phase 2 FOENIX-CCA2 study showed in 103 patients:
Two honest caveats. It was a single-arm study, so there was no comparison group. And because this is an accelerated approval, the label says continued approval may depend on results from a confirmatory trial. For comparison, the older FGFR inhibitor pemigatinib had a response rate of 37.0% and median overall survival of 17.5 months in its final FIGHT-202 results. The two studies weren't head to head, so they shouldn't be read as a direct match-up.
The label dose is 20 mg once daily, taken as five 4 mg tablets, with or without food, at about the same time each day.
Some of the newer cancer medicines, including Lytgobi, aren't sold through regular pharmacies in India. If your oncologist has prescribed one, Named Patient Program can help you import it in your own name through a regulated route. We don't prescribe or recommend treatment; that decision stays between you and your doctor.
You can read the full product details on the Lytgobi page, browse other cancer medicines under Oncology, or contact our team with your prescription and reports to ask about availability and timelines.
If you'd like to read more on related cancers, our guides on advanced colorectal cancer and what cancer is and how it's treated may help.
It's a cancer that starts in the thin tubes carrying bile from the liver to the intestine. Doctors also call it cholangiocarcinoma.
Often the first signs come when a duct is blocked: yellow skin and eyes, itching, dark urine and pale stools. Pain under the right ribs, poor appetite and weight loss can follow. These signs are more often caused by gallstones or hepatitis, but they always deserve a medical check.
If it's found early enough for the tumor to be removed, surgery gives the best chance of long-term control. Many cases are found later, so the aim then becomes controlling the disease for as long as possible with medicines. Your oncologist can tell you where you stand.
FGFR2 is a receptor that helps control cell growth. In some bile duct cancers, mainly intrahepatic ones, the FGFR2 gene fuses with another gene and keeps the growth signal switched on. A tumor test can find this, and if it's present, FGFR inhibitors such as Lytgobi are options after earlier treatment.
Through a regulated Named Patient Program, which imports the medicine in the patient's own name with a valid prescription from a qualified doctor, your diagnostic reports including the FGFR2 result, and Government of India ID proof.
We'd advise against it. Cancer medicines from unregulated sellers can be fake, expired or badly stored, and you can't tell by looking at the tablet. Named Patient Program sources Lytgobi from reliable global channels against a valid prescription, with pharmacist checks, temperature-controlled shipping and batch traceability, so what reaches you can be traced back to its source.
This article is for general information and isn't medical advice. Bile duct cancer is different for every person, and only your oncologist can say what's right for you based on your reports and health. Please don't start, stop or change any treatment because of something you read here.
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.com
Contact Us:
+91 9810469557
We get back to you shortly during our working hours.